RxDoctor Payments Data

Marie Borum, MD

Internal Medicine · Washington, DCNPI 1487616397

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $36,582 of the $42,274 with a category attached, or 86.5%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 87.4% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2023 at $17,199 and has fallen 92.2% since, to $1,343 in 2025. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$42,274in general payments, 2019–2025

Across 133 payments — averaging $317.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$37K
  • Exact Sciences$1K
  • Johnson & Johnson$756
  • AbbVie$657
  • Janssen Scientific Affairs, LLC$412
  • Pentax Of America, Inc.$402
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$36,58287%
  • Travel & lodging$1,4363%
  • Food & beverage$4,25610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,274 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$108,577
Medicare patients
318
Services billed
1,518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl26$425
Famotidine18$335
Pantoprazole Sodium26$291
Omeprazole14$164

Paid to pharmacies, not to this prescriber.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →